- Home
- WBS vs VRNA Comparison
WBS vs VRNA Comparison
Compare WBS & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- VRNA
- Stock Information
- Founded
- WBS 1935
- VRNA 2005
- Country
- WBS United States
- VRNA United Kingdom
- Employees
- WBS N/A
- VRNA N/A
- Industry
- WBS Major Banks
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- WBS Finance
- VRNA Health Care
- Exchange
- WBS Nasdaq
- VRNA Nasdaq
- Market Cap
- WBS 8.9B
- VRNA 8.3B
- IPO Year
- WBS N/A
- VRNA 2017
- Fundamental
- Price
- WBS $55.99
- VRNA $105.18
- Analyst Decision
- WBS Buy
- VRNA Buy
- Analyst Count
- WBS 14
- VRNA 11
- Target Price
- WBS $67.92
- VRNA $114.10
- AVG Volume (30 Days)
- WBS 1.5M
- VRNA 8.2M
- Earning Date
- WBS 07-17-2025
- VRNA 08-11-2025
- Dividend Yield
- WBS 2.86%
- VRNA N/A
- EPS Growth
- WBS 6.88
- VRNA N/A
- EPS
- WBS 4.92
- VRNA N/A
- Revenue
- WBS $2,486,236,000.00
- VRNA $118,535,000.00
- Revenue This Year
- WBS $8.33
- VRNA $893.95
- Revenue Next Year
- WBS $6.28
- VRNA $73.76
- P/E Ratio
- WBS $11.39
- VRNA N/A
- Revenue Growth
- WBS 2.89
- VRNA N/A
- 52 Week Low
- WBS $39.43
- VRNA $18.51
- 52 Week High
- WBS $63.99
- VRNA $105.50
- Technical
- Relative Strength Index (RSI)
- WBS 41.23
- VRNA 70.25
- Support Level
- WBS $58.66
- VRNA $104.58
- Resistance Level
- WBS $60.43
- VRNA $105.31
- Average True Range (ATR)
- WBS 1.48
- VRNA 0.22
- MACD
- WBS -0.67
- VRNA -0.64
- Stochastic Oscillator
- WBS 11.29
- VRNA 60.49
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.